EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

ACE2: Friend or Foe in Post-COVID-19 Neurodegeneration?

Svetlana V Kononova iD, Natalia V Bobkova iD, Rimma A Poltavtseva iD, Sergey Leonov iD, Gennadiy T Sukhikh iD

International Journal of Molecular Sciences · 17.11.2025 · 26 (22) · 11104

DOI: 10.3390/ijms262211104 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.11.2025. Verfasst von Svetlana V Kononova und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cell Biophysics, Federal Research Center "Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences", Pushc…. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme 2, COVID-19, Neurodegenerative Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 241 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Angiotensin-converting enzyme 2 (ACE2) is a key component of the renin–angiotensin system’s counter-regulatory pathway. ACE2 is a multifunctional protein whose location and form determine its catalytic and non-catalytic functions, including amino acid transport, the creation of structural complexes, adhesion, and involvement in signaling pathways. In addition, ACE2 influences neurotransmitter systems in the brain. As the main receptor for SARS-CoV-2, ACE2 has been the subject of increasing research interest. Although ACE2 levels in the brain are low, brain damage from SARS-CoV-2 increases the risk of neurodegenerative diseases. This review aims to clarify an important issue: does the temporary inactivation of ACE2 by the SARS-CoV-2 spike protein play a role in Alzheimer-like neurodegeneration, meaning that the protein may serve as a biomarker or therapeutic target?

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin-Converting Enzyme 2COVID-19Neurodegenerative DiseasesHumansSARS-CoV-2Spike Glycoprotein, CoronavirusRenin-Angiotensin SystemAnimalsAlzheimer DiseaseBrain

Stichwörter der Autor:innen

ACE2Alzheimer’s diseaseCOVID-19multifunctional proteinneurotransmitter systemsrenin–angiotensin system

Substanzen

Angiotensin-Converting Enzyme 2ACE2 protein, humanSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Institute of Cell Biophysics, Federal Research Center "Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences", Pushchino 142290, Russia.
  • National Medical Research Center for Obstetrics, Gynecology and Perinatology Named After Academician V.I. Kulakov, Moscow 117997, Russia.
  • Institute of Future Biophysics, Moscow Center for Advanced Studies, Moscow 123592, Russia.

ORCID-Profile: Svetlana V Kononova, Natalia V Bobkova, Rimma A Poltavtseva, Sergey Leonov, Gennadiy T Sukhikh

Förderung

  • Russian Science Foundation

Zitieren

APA

Kononova, S. V., Bobkova, N. V., Poltavtseva, R. A., Leonov, S., & Sukhikh, G. T. (2025). ACE2: Friend or Foe in Post-COVID-19 Neurodegeneration?. International Journal of Molecular Sciences, 26(22), 11104. https://doi.org/10.3390/ijms262211104

Vancouver

Kononova SV, Bobkova NV, Poltavtseva RA, Leonov S, Sukhikh GT. ACE2: Friend or Foe in Post-COVID-19 Neurodegeneration?. International Journal of Molecular Sciences. 2025;26(22):11104. doi:10.3390/ijms262211104

BibTeX
@article{Kononova2025,
  author = {Kononova, Svetlana V and Bobkova, Natalia V and Poltavtseva, Rimma A and Leonov, Sergey and Sukhikh, Gennadiy T},
  title = {ACE2: Friend or Foe in Post-COVID-19 Neurodegeneration?},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {22},
  pages = {11104},
  doi = {10.3390/ijms262211104}
}
Kostenlos starten →